Tags

Type your tag names separated by a space and hit enter

Recent data on hepatitis E.
Curr Opin Infect Dis. 2019 10; 32(5):475-481.CO

Abstract

PURPOSE OF REVIEW

Hepatitis E virus (HEV) has gained increased global recognition in recent years, particularly in developed countries. We summarized here a selection of the literature published since the 1st of June, 2017.

RECENT FINDINGS

Longitudinal studies are increasingly conducted in Europe, to determine trends in HEV prevalence. The spectrum of mammals infected with HEV and potentially capable to transmit it to humans has widened. New virological data on HEV repCon and pathogenicity have been reported and clinical features of HEV infections have been precised or newly described. Finally, there are some new data on the therapeutic management of HEV infections in various clinical settings.

SUMMARY

HEV emergence in developed countries appears to be based on improved diagnosis tools and increased awareness of clinicians that HEV transmission is essentially autochthonous and is a possible cause of life-threatening acute hepatitis, chronic hepatitis, cirrhosis, and extra-hepatic symptoms. In addition, the distribution of HEV strains evolves. Ribavirin remains to date the only specific treatment recommended for HEV infection, being efficient in the majority but not in all cases.

Authors+Show Affiliations

No affiliation info availableService d'Hépato-Gastro-Entérologie, Assistance Publique - Hôpitaux de Marseille (AP-HM), Service d'Hépato-Gastro-Entérologie, Centre Hospitalo-Universitaire Timone, Marseille, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

31361659

Citation

Colson, Philippe, and Claire Decoster. "Recent Data On Hepatitis E." Current Opinion in Infectious Diseases, vol. 32, no. 5, 2019, pp. 475-481.
Colson P, Decoster C. Recent data on hepatitis E. Curr Opin Infect Dis. 2019;32(5):475-481.
Colson, P., & Decoster, C. (2019). Recent data on hepatitis E. Current Opinion in Infectious Diseases, 32(5), 475-481. https://doi.org/10.1097/QCO.0000000000000590
Colson P, Decoster C. Recent Data On Hepatitis E. Curr Opin Infect Dis. 2019;32(5):475-481. PubMed PMID: 31361659.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent data on hepatitis E. AU - Colson,Philippe, AU - Decoster,Claire, PY - 2019/7/31/pubmed PY - 2020/7/30/medline PY - 2019/7/31/entrez SP - 475 EP - 481 JF - Current opinion in infectious diseases JO - Curr. Opin. Infect. Dis. VL - 32 IS - 5 N2 - PURPOSE OF REVIEW: Hepatitis E virus (HEV) has gained increased global recognition in recent years, particularly in developed countries. We summarized here a selection of the literature published since the 1st of June, 2017. RECENT FINDINGS: Longitudinal studies are increasingly conducted in Europe, to determine trends in HEV prevalence. The spectrum of mammals infected with HEV and potentially capable to transmit it to humans has widened. New virological data on HEV repCon and pathogenicity have been reported and clinical features of HEV infections have been precised or newly described. Finally, there are some new data on the therapeutic management of HEV infections in various clinical settings. SUMMARY: HEV emergence in developed countries appears to be based on improved diagnosis tools and increased awareness of clinicians that HEV transmission is essentially autochthonous and is a possible cause of life-threatening acute hepatitis, chronic hepatitis, cirrhosis, and extra-hepatic symptoms. In addition, the distribution of HEV strains evolves. Ribavirin remains to date the only specific treatment recommended for HEV infection, being efficient in the majority but not in all cases. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/31361659/Recent_data_on_hepatitis_E_ L2 - https://doi.org/10.1097/QCO.0000000000000590 DB - PRIME DP - Unbound Medicine ER -